A Phase II Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Venetoclax (Primary) ; Allopurinol; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Apr 2018 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 06 Dec 2017 Status changed from active, no longer recruiting to recruiting.
- 24 Aug 2017 Status changed from recruiting to active, no longer recruiting.